Organization
Citing tariffs, Illumina slashes guidance, confirms SEC’s Grail investigation is closed
Illumina, SEC, Acquisition (action), Evaluation, divestiture, Grail
In first oncology expert meeting under Makary, FDA spotlights cancer drugs from J&J, Pfizer, Roche and UroGen
United States Food and Drug Administration, oncology expert, J&J, Pfizer, Roche (company), UroGen
From deal to disaster: Drugmakers face a changed Washington as Trump embraces most favored nation prices
Prices, Transplant Registry Unified Management Program, MFN, Nation, Disasters, Medicaid, Policy, drugmakers, U.S.
NewAmsterdam’s pooled Phase 3 data; C4 seeks partners for solid tumor degrader
Pooled Sample, Obicetrapib, BROADWAY, NewAmsterdam, LDL-C, Cardiovascular Diseases
Capricor shares turn red as FDA plans deramiocel adcomm, likely the first under new commissioner
United States Food and Drug Administration, Capricor, deramiocel, Market, Review [Publication Type], Biologics License Application, first
Exclusive: Vertex drops AAV gene therapy research, tRNA therapy partnership
gene therapy, Dependovirus, Transfer RNA, Partnership, Industry, research, Safety
ElevAAte and the push for East Asian American leaders in biopharma
ElevAAte, biopharma, East Asian American, Leadership, leaders, Asian Americans, Mentorships, East Asian Americans, Ken Song
Biogen says Leqembi sales are improving slowly following lackluster launch
Leqembi, Biogen, Sales – occupational activity, Growth, Eisai, United States Food and Drug Administration, Improving (qualifier value)
Moderna expands effort to rein in costs in an uncertain environment
Moderna, Financial cost, Uncertainty, Environment